Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPX267 in Advanced Solid Tumors
NCT05958199Phase 1Suspended
- Sponsor
- NextPoint Therapeutics
- Start
- Jul 2023
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NPX267 in solid tumor, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and 11 more, sponsored by NextPoint Therapeutics. Primary endpoints: Incidence of Dose Limiting Toxicity at 21 days, Incidence of Treatment-Emergent Adverse Events at 12 weeks and 1 more. Started Jul 2023; status: suspended.
02
Drugs
NPX267
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)colorectal carcinoma (CRC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05958199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05958199.